

AV-101, a Prodrug GlyB-site Antagonist for the Treatment of Epilepsy and Neuropathic Pain

into an active metabolite, 7-chlorokynurenic acid (7-Cl-KYNA), which is one of the most potent antagonists of the regulatory GlyB-site of the NMDA receptor. In preclinical studies, VistaGen's AV-101 has 80-90% oral bio-availability, is rapidly and efficiently transported across the blood-brain barrier, and is converted into 7-Cl-KYNA in the brain and spinal cord — preferentially — at the site of neural damage, seizures and inflammation. AV-101 is active in acute and chronic models of epilepsy and three models of neuropathic pain. AV-101 has no findings in preclinical toxicity and metabolism that are a concern, and an IND on this compound soon will be filed consistent with guidance from a positive pre-IND meeting with the FDA.